Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis

@article{Muralidharan2017PopulationPA,
  title={Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis},
  author={K. K. Muralidharan and G. Kuesters and T. Plavina and M. Subramanyam and D. Mikol and Sreeja Gopal and I. Nestorov},
  journal={The Journal of Clinical Pharmacology},
  year={2017},
  volume={57}
}
  • K. K. Muralidharan, G. Kuesters, +4 authors I. Nestorov
  • Published 2017
  • Medicine
  • The Journal of Clinical Pharmacology
  • Natalizumab (humanized immunoglobulin G4 antibody targeting alpha‐4 integrins) is a highly efficacious treatment for relapsing‐remitting multiple sclerosis (RRMS) that has been in clinical use since 2006. However, natalizumab pharmacokinetic (PK) characteristics and concentration alpha‐4 integrin saturation relationships have not been well described in the scientific literature. Therefore, clinical data from 11 studies were pooled and analyzed to characterize the PK and pharmacodynamic (PD… CONTINUE READING
    19 Citations
    Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
    • 1
    • PDF
    Personalized extended interval dosing of natalizumab in MS
    • Highly Influenced
    The natalizumab wearing-off effect
    • 3
    • PDF

    References

    SHOWING 1-10 OF 31 REFERENCES
    Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    • 71
    • Highly Influential
    [Natalizumab in the treatment of multiple sclerosis].
    • 26
    A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
    • 2,632
    • PDF
    A controlled trial of natalizumab for relapsing multiple sclerosis.
    • 1,148
    • PDF